For Patients & Visitors

Doctor Details

Find a Doctor
Doctor Detail

Dr Andrea Wong

Photo of Dr Andrea Wong


  • Head & Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
  • Senior Consultant, Department of Oncology - Medical & Radiation, Ng Teng Fong General Hospital
  • Assistant Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore


MBChB (Hons), MRCP, M Med (Int Med)


Medical Oncology

Special Interests:

Early phase clinical trials, developmental therapeutic - cancer cell metabolism as a therapeutic target


Dr Andrea Wong completed her undergraduate medical degree at the University of Glasgow, and obtained her postgraduate qualifications from the Royal College of Physicians, United Kingdom as well as the National University of Singapore. She specializes in breast and brain cancers and actively contributes to cancer research through her role as an investigator in several clinical trials conducted at the National University Cancer Institute, Singapore (NCIS).

She is currently performing translational research work related to the development of novel targeted therapies for the treatment of advanced cancer in her capacity as an Adjunct Research Fellow at the Cancer Science Institute, Singapore. She has received multiple research grants for her work, including the Singapore National Medical Research Council Transition Award in 2018. In addition, she has authored several publications in peer-reviewed oncology and pharmacogenetics journals, and is a member of the Singapore Society of Oncology.


  • 2018 - 2021: National Medical Research Council (NMRC) Transition Award
  • 2018: National Medical Research Council (NMRC) Clinican Investigator Salary Support Programme
  • 2017 - 2018: NUHS Clinician Scientist Programme Award

Journals & Publications

  1. J Li, JQ Eu, LR Kong, L Wang, YC Lim, BC Goh, A Wong. "Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy" Molecules 2020, 25(20), 4831 (IF 3.27)
  2. A Wong, G Bellot, JL Hirpara, S Pervaiz. "Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer' Biochem Pharmacol (2019) DOI: 10.1016/j.bcp.2019.01.020 (IF 4.82)
  3. N Ngoi, JQ Eu, JL Hirpara, LZ Wang, JSJ Lim, SC Lee, YC Lim, S Pervaiz, BC Goh, A Wong. 'Targeting Cell Metabolism as Cancer Therapy' Antioxidants and Redox Signaling (2019) DOI 10.1089/ars.2019.7947 (IF 5.83)
  4. M Lee, J.L. Hirpara, JQ Eu, G. Sethi, Wang L, B.C. Goh, A Wong. 'Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors'. Redox Biol (2018) DOI: 10.1016/j.redox.2018.101073 (IF 7.6)
  5. A Wong, X Xiang, PS Ong, EQY Mitchell, N Syn, I Wee, AP Kumar, WP Yong, G Sethi, BC Goh, P Ho, L Wang. 'A Review on Liquid Chromatography Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.' Pharmaceutics (2018), DOI: 10.3390/pharmaceutics10040221 (IF: 3.9)
  6. A Wong, J.L. Hirpara, S. Pervaiz, J.Q. Eu, G. Sethi & B.C. Goh (2017): Do STAT3 inhibitors have potential in the future for cancer therapy?, Expert Opinion on Investigational Drugs, DOI: 10.1080/13543784.2017.1351941 (IF 5.5)
  7. A Wong, R Sundar, TT Wang, TC Ng, B Zhang, SH Tan, T Soh, A Pang, CS Tan, S Ow, LZ Wang, J Mogro, J Ho, A Jeyasekharan, Y Huang, CH Thng, CW Chan, M Hartman, P Iau, S Buhari, BC Goh, SC Lee. 'Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer' Oncotarget (2016) DOI: 10.18632/oncotarget.11596 (IF 5.1)
  8. A Wong, R Soo, D Tan, SC Lee, J Lim, P Marban, LR Kong, YJ Lee, LZ Wang, WL Thuya, R Soong, MQ Yee, TM Chin, MT Cordero, BR Asuncion, B Pang, S Pervaiz, JL Hirpara, A Sinha, WW Xu, M Yuasa, T Tsunoda, M Motoyama, T Yamauchi, BC Goh, 'Phase I and Biomarker Study of OPB-51602, a Novel Signal Transducer and Activator of Transcription (STAT) 3 Inhibitor, in Patients with Refractory Solid Malignancies'. Annals of Oncology (2015), 26 (5): 998-1005. (IF 11.8)
  9. Y Bao, G Oguz, WC Lee, PL Lee, K Ghosh, J Li, P Wang, P Lobie, H Ditzel, A Wong, EY Tan, SC Lee, and Q Yu. "EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy" Nat Comms (2020), 11: 5878 (IF 11.8)
  10. V Heong, D Tay, S Goh, B Wee, TZ Tan,R Soo, B Pang, D Lim, A Gopinathan, S Ow, CE Chee, BC Goh, SC Lee, WP Yong, A Wong, R Soong, D Tan 'Whole exome sequencing of multi-regional biopsies from metastatic lesions to evaluate actionable truncal mutations using a single-pass percutaneous technique' Cancers (2020) Article cancers-791356 (IF 6.1)

Professional Memberships

  • American Society of Clinical Oncology
  • Singapore Society of Oncology

Last updated on
Best viewed with Chrome 79.0, Edge 112.0, Firefox 61.0, Safari 11
National University Health System
  • National University Hospital
  • Ng Teng Fong General Hospital
  • Alexandra Hospital
  • Jurong Community Hospital
  • National University Polyclinics
  • Jurong Medical Centre
  • National University Cancer Institute, Singapore
  • National University Heart Centre, Singapore
  • National University Centre for Oral Health, Singapore
  • NUHS Diagnostics
  • NUHS Pharmacy
  • Yong Loo Lin School of Medicine
  • Faculty of Dentistry
  • Saw Swee Hock School of Public Health
Back to Top